Written by Zachary Newland, Founding Partner. Last updated September 16, 2026.

Mid-Level Practitioner Prescribing Authority: Federal Criminal Exposure for Nurse Practitioners, Physician Assistants, and Pharmacies

On This Page

• What Is a Mid-Level Practitioner Under Federal Law?
• How Mid-Level Practitioner Prescribing Authority Works
• Federal Criminal Exposure for Exceeding Prescriptive Authority
• What Mid-Level Practitioners and Pharmacies Should Do Now
• How Evergreen Attorneys Can Help
• Frequently Asked Questions

Mid-level practitioner prescribing authority is one of the most misunderstood areas where state scope-of-practice law intersects with federal criminal enforcement. A nurse practitioner or physician assistant who writes a controlled substance prescription that exceeds the limits set by state law does not simply face a licensing board complaint.

That prescription can become the basis for a federal investigation, DEA enforcement action, or criminal prosecution under 21 U.S.C. § 841, the same statute used to charge drug traffickers. Pharmacies that fill those prescriptions face parallel exposure.

If you are a mid-level prescriber, supervising physician, or pharmacy owner under federal investigation involving controlled substance prescribing, the distinction between a compliance issue and a federal crime turns on facts you need to understand now.

If you are a nurse practitioner, physician assistant, or other mid-level practitioner who is under federal investigation, contact Evergreen Attorneys today at 303-948-1489. We will give you a one-on-one confidential case assessment today.

What Is a Mid-Level Practitioner Under Federal Law?

Federal regulations define a “mid-level practitioner” as an individual practitioner, other than a physician, dentist, veterinarian, or podiatrist, who is authorized by the jurisdiction in which they practice to dispense controlled substances in the course of professional practice. This definition appears at 21 C.F.R. § 1300.01(b)(28). The category includes nurse practitioners, physician assistants, certified nurse-midwives, clinical nurse specialists, optometrists with prescriptive privileges, and other clinicians whose state licensing statutes permit controlled substance prescribing.

The critical point is that federal law does not independently grant prescriptive authority to any mid-level practitioner. Instead, the federal regulatory framework recognizes whatever authority the practitioner’s state has chosen to provide. When a mid-level practitioner applies for a DEA registration under 21 C.F.R. § 1301.13(a), the DEA confirms that the applicant already possesses state-authorized prescriptive authority for the requested drug schedules. The DEA number does not expand that authority beyond what state law permits.

How Mid-Level Practitioner Prescribing Authority Works

Mid-level practitioner prescribing authority for controlled substances is governed by a layered system. State scope-of-practice statutes establish the outer boundary. Within that boundary, many states impose additional conditions: collaborative practice agreements with supervising physicians, formulary restrictions, schedule-specific limitations, days-supply caps, and documentation requirements.

The variation across states is significant. Some states allow nurse practitioners full independent prescriptive authority across all five controlled substance schedules. Others limit mid-level practitioners to Schedules III through V, prohibit Schedule II prescribing entirely, or permit Schedule II prescribing only with a supervising physician’s co-signature or only in specific clinical settings. The DEA publishes a state-by-state reference of mid-level practitioner controlled substance authority by discipline, but that document summarizes general categories and does not replace a careful reading of each state’s statutes and administrative rules.

Under 21 C.F.R. § 1306.03, a prescription for a controlled substance is valid only if it is issued by a practitioner who is authorized by the applicable jurisdiction and registered with the DEA (or exempt from registration) to prescribe that substance. A prescription written by a mid-level practitioner who lacks state authority for the prescribed schedule, who writes outside the terms of a required collaborative agreement, or whose prescribing exceeds a state-imposed quantity limit is not a lawful prescription under federal law.

Colorado’s Supreme Court-proven Federal Criminal Defense Team.

Federal Criminal Exposure for Exceeding Prescriptive Authority

Exceeding mid-level practitioner prescribing authority is not simply a regulatory infraction. When the conduct is knowing or intentional, it can trigger federal criminal liability under the Controlled Substances Act.

The Core Federal Statute: 21 U.S.C. § 841

Section 841 of the Controlled Substances Act prohibits any person from knowingly or intentionally manufacturing, distributing, or dispensing a controlled substance except as authorized. The definitions in 21 U.S.C. § 802 make clear that “dispense” includes prescribing, and “practitioner” includes any person registered or exempt from registration under the Act.

A mid-level practitioner who writes prescriptions outside the bounds of state-authorized scope is, under this framework, dispensing without authorization.

The Supreme Court clarified the mens rea standard in Ruan v. United States, 597 U.S. 450 (2022). The Court held that to convict a practitioner under § 841, the government must prove the practitioner subjectively knew or intended that their prescribing conduct was unauthorized. This standard protects practitioners who make good-faith mistakes about the boundaries of their authority. It does not, however, shield practitioners who deliberately ignore scope limitations or prescribe in knowing violation of collaborative agreement terms.

Parallel Healthcare Fraud and False Claims Act Risk

When a mid-level practitioner bills Medicare, Medicaid, or a federal healthcare program for prescriptions written outside the practitioner’s authorized scope, the government may also pursue charges under the federal healthcare fraud statute, 18 U.S.C. § 1347, or the federal False Claims Act. The theory is straightforward: a claim for reimbursement that represents a prescription as lawfully issued, when it was not, constitutes a false or fraudulent claim. This can add years of additional prison exposure and treble-damages False Claims Act liability.

Pharmacies, DME suppliers whose orders depend on mid-level prescriptions, and supervising physicians can all be drawn into these investigations as co-conspirators or aiders and abettors.

One very prominent example of this is the DONE prosecution: https://www.justice.gov/opa/pr/founderceo-and-clinical-president-digital-health-company-convicted-100m-adderall

What Mid-Level Practitioners and Pharmacies Should Do Now

If you are a mid-level practitioner, supervising physician, or pharmacy facing questions about prescriptive authority and federal exposure, these steps are critical:

1. Identify the specific controlled substance schedules your state license and any collaborative practice agreement authorize you to prescribe. Do not rely on assumptions or what colleagues tell you is permissible.
2. Confirm that your DEA registration reflects only the schedules for which you have current, documented state authority. A DEA number listing Schedule II does not authorize Schedule II prescribing if your state or collaborative agreement prohibits it.
3. Review your prescribing history for any prescriptions that may have exceeded your authorized scope, particularly Schedule II prescriptions if your state restricts or prohibits them for your discipline.
4. Do not alter, destroy, or backdate any prescribing records, collaborative practice agreements, or patient charts. Destruction of records during an investigation creates separate federal obstruction exposure.
5. If you receive a DEA or OIG subpoena, a target letter, or contact from federal investigators, do not respond or provide documents before consulting federal defense counsel.

How Evergreen Attorneys Can Help

Evergreen Attorneys represents mid-level practitioners, supervising physicians, and pharmacies facing federal investigations and charges related to controlled substance prescribing. The firm’s federal white collar crime lawyers analyze the intersection of state scope-of-practice rules, DEA registration requirements, and federal criminal statutes to determine whether the government can establish the knowing or intentional conduct required under Ruan v. United States.

Evergreen Attorneys’ work in these matters includes reviewing collaborative practice agreements and state licensing terms, assessing prescribing data for defensible patterns, responding to DEA administrative actions, and defending practitioners and pharmacies in federal drug crimes and healthcare fraud prosecutions.

Zachary Newland has appeared as counsel of record in more than 120 federal cases since 2016, including matters involving controlled substance enforcement and healthcare fraud.

Frequently Asked Questions

Does a DEA registration expand a mid-level practitioner’s authority to prescribe controlled substances?

No. A DEA registration confirms that a mid-level practitioner already holds state-authorized prescriptive authority for the requested schedules. The DEA number is a federal registration, not a grant of prescriptive scope. If a practitioner’s state license or collaborative practice agreement limits prescribing to Schedules III through V, the DEA registration does not authorize Schedule II prescribing. Using a DEA registration to prescribe outside state-authorized scope can constitute unauthorized dispensing under the Controlled Substances Act.

Can physician assistants prescribe Schedule II controlled substances under federal law?

Federal law does not independently answer this question. Whether a physician assistant can prescribe Schedule II controlled substances depends entirely on the laws of the state where the physician assistant practices and the terms of any required supervisory or collaborative agreement. Some states permit it with specific documentation and oversight requirements; others prohibit it entirely. A physician assistant who prescribes Schedule II drugs in a state that does not authorize it is prescribing without legal authority, which can form the basis for federal criminal charges under 21 U.S.C. § 841.

What triggers a federal investigation into a mid-level practitioner’s prescribing?

Federal investigations into mid-level practitioner prescribing typically originate from prescription monitoring program alerts showing unusual volume or scheduling patterns, pharmacy reports of prescriptions that appear to exceed the prescriber’s authority, Medicare or Medicaid billing audits revealing controlled substance claims from practitioners whose scope does not support them, or complaints from supervising physicians or employers. The DEA Diversion Control Division may open an administrative investigation, which can be referred to a U.S. Attorney’s Office for criminal prosecution if evidence of knowing or intentional unauthorized prescribing emerges.

When should a mid-level practitioner or pharmacy involve federal defense counsel?

Federal defense counsel should be involved as soon as there is any indication that prescribing conduct is under federal scrutiny. Specific triggers include receiving a DEA letter of inquiry or show-cause order, a federal grand jury subpoena for prescribing records, a target or subject letter from a U.S. Attorney’s Office, contact from DEA agents or HHS-OIG investigators, or notification from an employer that prescribing patterns are under review. Early involvement of counsel can shape the response to subpoenas, protect against self-incrimination, and position the practitioner or pharmacy to contest administrative actions before they become criminal charges.

If you are facing a federal investigation or charges related to mid-level practitioner prescribing authority, contact Evergreen Attorneys at (303) 948-1489 for an immediate case evaluation.